The combination of alemtuzumab [Continuous intravenous infusion (civ) followed by subcutaneous injection (sc)] plus rituximab has activity in patients (pts) with relapsed chronic lymphocytic leukemia (CLL).

被引：3

作者：

Faderl, Stefan

Ferrajoli, Alessandra

Wierda, William G.

O'Brien, Susan

Ravandi-Kashani, Farhad

Fayad, Luis

Thomas, Deborah

Kantarjian, Hagop

Browning, Mary L.

Keating, Michael J.

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1182/blood.V108.11.2827.2827

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2827

引用

页码：800A / 800A

页数：1